Dynamic Glucocorticoid Dosing for CAH via CRF1 Antagonist Feedback
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Congenital Adrenal Hyperplasia (CAH) often require high doses of glucocorticoids to manage cortisol deficiency and excess androgen production, leading to increased cardiovascular risk factors and bone mineral density issues, with limited options for precise hormone level control.
Innovation Solution
Administering a steroid or its pharmaceutically acceptable salt in combination with a corticotropin-releasing factor type-1 (CRF1) antagonist to adjust doses based on individual steroid hormone levels, reducing the steroid dose when levels are below certain thresholds and maintaining doses when levels are elevated, to achieve normalized hormone levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If high doses of glucocorticoids are administered to manage cortisol deficiency and excess androgen production, then hormone level control is improved, but cardiovascular risk factors and bone mineral density issues increase
Solution Approach 1:
The patent implements a feedback mechanism where steroid hormone levels are monitored and used to adjust glucocorticoid dosing. When steroid levels are above the upper limit of the reference range, the glucocorticoid dose is reduced; when levels are below, the dose is increased. This closed-loop control system prevents both under-treatment and over-treatment, resolving the contradiction between achieving precise hormone control and avoiding harmful side effects from excessive dosing.
Solution Approach 2:
The patent transitions from static fixed-dose glucocorticoid therapy to dynamic dose adjustment based on individual patient response. The dosing regimen is continuously adapted according to measured steroid hormone levels, allowing the treatment to optimize efficacy while minimizing toxic effects. This dynamic approach enables precise hormone control without the need for consistently high doses that cause cardiovascular and bone health problems.
2Reliability
If fixed high doses of glucocorticoids are administered, then cortisol deficiency is managed, but precise hormone level control is limited
Solution Approach 1:
The patent employs real-time feedback from steroid hormone level measurements to guide glucocorticoid dosing decisions. This ensures that cortisol deficiency is reliably managed while achieving precise control over hormone levels. The feedback loop allows the treatment to respond to individual patient variability and fluctuating hormone levels, maintaining reliable cortisol replacement without the imprecision of fixed dosing.
Data Source
AI summary
Patients with congenital adrenal hyperplasia (CAH) need adequate care and treatment in order to lead normal lives. Hence, there is a need for new methods of treating CAH. This disclosure provides new compounds, salts, compositions and uses thereof in the treatment of CAH.